Total Payments
$128,888
2024 Payments
$14.94
Companies
20
Transactions
102
Medicare Patients
69
Medicare Billing
$12,702
Payment Breakdown by Category
Consulting$68,808 (53.4%)
Research$47,489 (36.8%)
Education$4,756 (3.7%)
Other$3,602 (2.8%)
Travel$2,466 (1.9%)
Food & Beverage$1,768 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $68,808 | 21 | 53.4% |
| Unspecified | $47,489 | 11 | 36.8% |
| Education | $4,756 | 2 | 3.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,602 | 5 | 2.8% |
| Travel and Lodging | $2,466 | 10 | 1.9% |
| Food and Beverage | $1,768 | 53 | 1.4% |
Payments by Type
General
$81,399
91 transactions
Research
$47,489
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $60,321 | 21 | $0 (2022) |
| Janssen Research & Development, LLC | $27,060 | 9 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $8,721 | 26 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $8,131 | 2 | $0 (2023) |
| PFIZER INC. | $7,920 | 7 | $0 (2022) |
| Kite Pharma, Inc. | $5,987 | 7 | $0 (2023) |
| AbbVie, Inc. | $5,167 | 8 | $0 (2018) |
| AstraZeneca UK Limited | $2,740 | 1 | $0 (2022) |
| F. Hoffmann-La Roche AG | $2,332 | 3 | $0 (2018) |
| GlaxoSmithKline, LLC. | $165.04 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.94 | 1 | Astellas Pharma US Inc ($14.94) |
| 2023 | $9,474 | 9 | Kite Pharma, Inc. ($5,987) |
| 2022 | $20,921 | 6 | Janssen Research & Development, LLC ($11,000) |
| 2021 | $11,200 | 5 | Janssen Research & Development, LLC ($6,600) |
| 2020 | $16,463 | 8 | Janssen Research & Development, LLC ($9,460) |
| 2019 | $11,730 | 11 | Celgene Corporation ($10,365) |
| 2018 | $25,823 | 42 | Celgene Corporation ($15,097) |
| 2017 | $33,263 | 20 | Celgene Corporation ($31,157) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/23/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Oncology | ||||||
| 10/27/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,460.00 | General |
| 05/08/2023 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Consulting Fee | Cash or cash equivalent | $5,290.00 | General |
| Category: CELLT | ||||||
| 04/28/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: CELLT | ||||||
| 04/28/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $19.65 | General |
| Category: CELLT | ||||||
| 04/22/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $517.22 | General |
| Category: CELLT | ||||||
| 04/22/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CELLT | ||||||
| 04/22/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $49.97 | General |
| Category: CELLT | ||||||
| 04/22/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: CELLT | ||||||
| 09/27/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 05/06/2022 | E.R. Squibb & Sons, L.L.C. | — | Education | In-kind items and services | $4,670.50 | General |
| 01/17/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $6,600.00 | General |
| 01/17/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| 01/12/2022 | PFIZER INC. | DAURISMO (Drug) | — | In-kind items and services | $780.00 | Research |
| Study: AML CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 01/11/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $1,730.00 | General |
| 11/05/2021 | PFIZER INC. | — | — | In-kind items and services | $1,400.00 | Research |
| Study: AML CLINICAL PUBLICATION PROGRAM | ||||||
| 10/19/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 08/27/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 07/23/2021 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: AML CLINICAL PUBLICATION PROGRAM | ||||||
| 02/03/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 12/25/2020 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 12/25/2020 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 12/18/2020 | Celgene Corporation | REBLOZYL (Biological) | Consulting Fee | Cash or cash equivalent | $1,972.50 | General |
| Category: Hematology | ||||||
| 11/23/2020 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,520.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACE-536-MDS-001 | Celgene Corporation | $28,284 | 1 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $10,365 | 3 |
| AML CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,650 | 5 |
| ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $2,025 | 1 |
| A PHASE I/II, OPEN-LABEL, 2 ARM STUDY TO INVESTIGATE THE SAFETY, CLINI | GlaxoSmithKline, LLC. | $165.04 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 14 | 40 | $21,400 | $2,823 |
| 2022 | 1 | 16 | 62 | $31,310 | $5,336 |
| 2021 | 1 | 15 | 68 | $25,500 | $2,115 |
| 2020 | 2 | 24 | 48 | $20,195 | $2,428 |
Total Patients
69
Total Services
218
Medicare Billing
$12,702
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 40 | $21,400 | $2,823 | 13.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 62 | $31,310 | $5,336 | 17.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 15 | 68 | $25,500 | $2,115 | 8.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 29 | $11,045 | $1,264 | 11.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 19 | $9,150 | $1,164 | 12.7% |
About Dr. Amit Verma, MD
Dr. Amit Verma, MD is a Internal Medicine healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033299524.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Verma, MD has received a total of $128,888 in payments from pharmaceutical and medical device companies, with $14.94 received in 2024. These payments were reported across 102 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($68,808).
As a Medicare-enrolled provider, Verma has provided services to 69 Medicare beneficiaries, totaling 218 services with total Medicare billing of $12,702. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Bronx, NY
- Active Since 10/17/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1033299524
Products in Payments
- Luspatercept (Drug) $51,195
- Yescarta (Drug) $5,987
- Venclexta (Drug) $5,167
- PROMACTA (Drug) $4,516
- DAURISMO (Drug) $3,320
- TECENTRIQ (Biological) $2,332
- REBLOZYL (Biological) $1,973
- Reblozyl (Drug) $935.00
- JADENU (Drug) $246.46
- IMBRUVICA (Drug) $127.76
- TASIGNA (Drug) $113.07
- Abraxane (Drug) $43.33
- JAKAFI (Drug) $41.53
- AFINITOR (Drug) $40.35
- INJECTAFER (Drug) $35.74
- QINLOCK (Drug) $26.66
- KISQALI (Drug) $23.85
- XTANDI (Drug) $23.71
- VOTRIENT (Drug) $22.24
- CALQUENCE (Drug) $19.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bronx
Timothy Kanter, M.d, M.D
Internal Medicine — Payments: $865,160
Internal Medicine $865,160
Dr. Jason Leider, M.d, M.D
Internal Medicine — Payments: $759,257
Internal Medicine $759,257
Bulent Atac, Md, MD
Internal Medicine — Payments: $654,500
Internal Medicine $654,500
Shervin Mortazavi, M.d, M.D
Internal Medicine — Payments: $402,598
Internal Medicine $402,598
Dr. Elizabeth Jenny-Avital
Internal Medicine — Payments: $176,355
Internal Medicine $176,355
Vivek Gumaste, M.d, M.D
Internal Medicine — Payments: $163,229
Internal Medicine $163,229